Abstract
Thirteen patients with cisplatin-refractory germ cell tumors were treated on a Phase II trial with pyrazoloacridine. Pyrazoloacridine was given intravenously at 600 mg/m2 every three weeks. The median nadir leucocyte count was 2.5 cells/mm3, hemoglobin was 10.8 g/dl, and platelet count was 126,000 cells/m3. None of the thirteen evaluable patients achieved a major response. Pyrazoloacridine is not efficacious in the treatment of cisplatin-refractory germ cell tumors.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase II
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Acridines / adverse effects
-
Acridines / therapeutic use*
-
Adult
-
Antineoplastic Agents / therapeutic use*
-
Cisplatin / therapeutic use*
-
Female
-
Germinoma / drug therapy*
-
Humans
-
Male
-
Mediastinal Neoplasms / drug therapy
-
Middle Aged
-
Pyrazoles / adverse effects
-
Pyrazoles / therapeutic use*
-
Testicular Neoplasms / drug therapy
Substances
-
Acridines
-
Antineoplastic Agents
-
Pyrazoles
-
NSC 366140
-
Cisplatin